Invetso Quality Score — ICCC

ImmuCell Corporation · 5.8/10 — Balanced · Updated September 2026

5.8Balanced

Last updated: September 2026

Factor Snapshot

Durability🟡 Moderate
Capital Efficiency🟡 Moderate
Growth Quality🟡 Moderate
Risk Profile🟡 Moderate
Capital Allocation🟡 Moderate
Scalability🟡 Moderate

Invetso Quality Score

🟡 5.8 (Moderate)

Core Drivers

Balanced but not dominant competitive position: ICCC has some durability from switching friction and niche positioning, but the moat is not strong enough to create clear pricing power or structural separation from global peers.

Adequate capital returns with limited compounding proof: ROIC is acceptable and leverage is manageable, yet the evidence does not show the kind of multi-year compounding or operating leverage that would lift the company into a higher-quality tier.

Growth is viable, but execution-dependent: The business can keep expanding, but growth appears more dependent on steady execution and working-capital discipline than on powerful structural tailwinds or exceptional scalability.

Peer-relative resilience is decent, not leading: Liquidity and balance-sheet restraint reduce downside, but the company still sits around the middle of the peer set rather than among the more resilient or more scalable franchises.

Key Constraints

Working-capital drag limits reinvestment speed: The long cash conversion cycle slows capital recycling and weakens the company’s ability to compound faster than more efficient peers.

Moat quality is incomplete: Switching costs exist, but weak network effects, limited cost advantage, and only modest scale benefits keep long-term defensibility from becoming a decisive edge.

Growth visibility is not strong enough to justify a premium quality profile: Missing multi-year compounding evidence and only moderate operating leverage leave the upside path less compelling than that of leading global peers.

Synthesis

ICCC presents a middle-tier investment quality profile: the business is stable enough to support continued operation and selective expansion, but it does not show the kind of durable moat or capital efficiency that typically defines leading compounders. The most important positive is that downside appears contained by reasonable liquidity and manageable leverage, which reduces the risk of a severe balance-sheet problem. However, that resilience is offset by a long cash conversion cycle and only moderate evidence of scalable reinvestment, which slows the pace at which value can compound. Relative to global peers, ICCC looks above the weakest operators but clearly below the franchises with stronger pricing power, faster cash generation, and more visible multi-year growth acceleration. The result is a profile that is constructive but not commanding, with upside that depends heavily on execution rather than on a clearly superior structural advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ImmuCell Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →